A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).

@article{Sherman2011API,
  title={A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).},
  author={Steven I. Sherman and Barbara Jarzab and Maria E Cabanillas and Lisa F. Licitra and F. Rossi Pacini and Renato Alas Martins and Bridget Robinson and Douglas Ball and John McCaffrey and Manisha Hasmukhray Shah and Donald L. Bodenner and Roger Allison and Katie L. Newbold and Rossella Elisei and James P. O'Brien and Martin Schlumberger},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={5503}
}
5503 Background: E7080 is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT and PDGFRβ. In phase I studies of E7080 partial responses (PR) were observed in thyroid as well as melanoma, endometrial, and renal cancers. METHODS Between Oct 2, 2008 and Feb 5, 2010, patients (pts) with advanced, RAI-refractory DTC (papillary, follicular or Hurthle Cell) and disease progression demonstrated by RECIST during the prior 12 months were enrolled. Pts may have received prior VEGFR… CONTINUE READING
40 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

Similar Papers

Loading similar papers…